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Autologous Hematopoietic StemCell Transplantation
—10 Years of Data From a Developing Country
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ABSTRACT
Intensive chemotherapy followed by autologous stem cell transplantation is the treatment of
choice for patients with hematological malignancies. The objective of the present study was to eval-
uate the outcomes of patients with mainly lymphoma andmultiple myeloma after autologous stem
cell transplant. The pretransplant workup consisted of the complete blood count, an evaluation of
the liver, kidney, lung, and infectious profile, chest radiographs, and a dental review. For lymphoma,
all patients who achieved at least a 25% reduction in the disease after salvage therapywere included
in the study. Mobilization was done with cyclophosphamide, followed by granulocyte colony-
stimulating factor, 300 mg twice daily. The conditioning regimens included BEAM (carmustine,
etoposide, cytarabine, melphalan) and high-dose melphalan. A total of 206 transplants were per-
formed from April 2004 to December 2014. Of these, 137 were allogeneic transplants and 69 were
autologous. Of the patients receiving an autologous transplant, 49 were male and 20 were female.
Of the 69 patients, 26 underwent transplantation for Hodgkin’s lymphoma, 23 for non-Hodgkin’s lym-
phoma, and 15 formultiplemyelomaand4and1 for Ewing’s sarcomaandneuroblastoma, respectively.
Themedian age6 SDwas 346 13.1 years (range, 4–64). Amean of 4.73 1086 1.7 mononuclear cells
per kilogram were infused. The median time to white blood cell recovery was 18.2 6 5.34 days.
Transplant-related mortality occurred in 10 patients. After a median follow-up period of 104 months,
the overall survival rate was 86%. High-dose chemotherapy, followed by autologous stem cell trans-
plant, is an effective treatment option for patients with hematological malignancies, allowing further
consolidation of response. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:873–877
SIGNIFICANCE
This report presents the results of autologous stem cell transplant in hematological malignancies
from a developing country. This is a large cohort from Pakistan, with overall survival comparable
to that from international data.
INTRODUCTION
Autologous stem cell transplantation (ASCT) is
an alternative treatment modality for lympho-
mas, multiple myeloma, and a few solid tumors
[1]. In the 1970s, it was postulated that stem cell
mobilization was possible after a high level of
progenitor cells were observed in the blood of
patients who had received cyclophosphamide
chemotherapy [2]. In 1984, the CD34 marker was
identifiedonhematopoietic stemcells. This second
discovery led to a swift increase in the understand-
ing andmanipulation of ASCT, which resulted in its
significant growth [3].
Autologous hematopoietic stem cell trans-
plantation (HSCT) is used to bridge hematopoietic
failure during high-dose chemotherapy for the
treatment of tumors of the hematopoietic system
that are adequately sensitive to this treatment. In
this sense, autologous stem cell support is not a
“transplant”; however, the term “autologousHSCT”
is commonly used. This procedure was initially de-
veloped forpatientswith leukemiawithout a sibling
donor for allogeneic transplant. Later, it became
the standard of care for patients with lymphoma,
myeloma, and some childhood neoplasms [4].
More than one half of the stem cell transplants
performed in Europe are autologous. The European
BoneMarrow Transplant (EBMT) annual activity sur-
vey for 2011 reported a58% rateof autologous stem
celltransplants.MostoftheseASCTswereperformed
for lymphoid malignancies (plasma cell disorders,
46%; non-Hodgkin’s lymphoma, 30%; Hodgkin’s dis-
ease, 11%). The focus from marrow to peripheral
blood as a source of stem cells occurred in the early
1990s forASCT.Recentdatanowsuggest that99%of
all autologous transplant procedures use peripheral
blood as the source [5].
The 2011 Center for International Blood and
BoneMarrowTransplant Research (CIBMTR) data
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showed that 12,047 autologous transplants were performed, for
whichmultiplemyelomaand lymphomaswere themost common
indications [6].
The standard treatment for B-cell non-Hodgkin’s lymphoma
(NHL) includes chemotherapy with rituximab.
A Cochrane analysis published in 2013 evaluated 2 random-
ized control trials (n = 157) of relapsed Hodgkin’s lymphoma
(HL) patients that included 2 treatment arms: high-dose chemo-
therapy (HDCT) plus autologous stem cell transplantation versus
conventional chemotherapy without autologous stem cell trans-
plantation. The difference in progression-free survival was sta-
tistically significant for patients treated with HDCT followed
by ASCT compared with patients treated with conventional che-
motherapy alone (hazard ratio [HR], 0.55; 95% confidence inter-
val [CI] 0.35–0.86; p = .009) [7].
Two systematic reviews assessed the efficacy of high-dose
chemotherapy with single ASCT versus conventional chemother-
apy in patients with multiple myeloma. The pooled results have
showna statistically nonsignificant difference in survival between
high-dose chemotherapy plus stem cell rescue (HR, 0.92; 95%
CI, 0.74–1.13; p = .40) versus chemotherapy. For the outcome
of progression-free survival, a statistically significant benefit was
associated with high-dose chemotherapy plus stem cell rescue
(HR, 0.75; 95% CI, 0.59–0.96; p = .02) [8].
Kumar et al. [9] in a study from India in 2010 reported a me-
dian overall and event-free survival of 78 and 28months, respec-
tively, for patients undergoing autologous stemcell transplant for
Hodgkin’s and non-Hodgkin’s lymphoma.
In Pakistan, use of the hematopoietic stem cell transplant
procedure started in 1995. Because of the burden of nonma-
lignant diseases such asb-thalassemia major and aplastic ane-
mia, the number of allogeneic transplants have outnumbered
the number of autologous transplant procedures. Neverthe-
less, we have a significant burden of lymphoid malignancies
in young patients for whom autologous hematopoietic trans-
plantation is the only curative option. In the present report,
we present our initial data on the frequency and outcomes
of autologous stem cell transplants performed in our center
from 2004 to 2014.
MATERIALS AND METHODS
We retrospectively analyzed the data from all patients who un-
derwent autologous stem cell transplant from April 2004 to
December 2014. The patients were considered to have chemo-
sensitive disease if they had had a complete response (CR) or par-
tial remission at ASCT. These included patients with HL, NHL, and
multiple myeloma. Patients with a minimal response (25%–50%
response), progressive, or refractory disease were considered
to have chemoresistant disease.
Our institute is a tertiary care, private hospital with 29 beds
dedicated to cancer patients. In addition, 54 beds are available
in a day care center exclusively for hematology/oncology patients
for chemotherapy administration and blood and/or blood prod-
uct transfusion. The transplant unit was established in 2004
andwas initially a 2-bed facility thatwas upgraded to 4 beds later.
Pakistan’s gross domestic product in 2013 was reported to be
$232.3 billion. The average household income ranges from
$1,200 to $1,500 annually. Therefore, affording an expensive pro-
cedure such as stem cell transplant is very challenging. Neverthe-
less, the cost of the procedure is met by the patients themselves,
philanthropists, and medical insurance. Patients are referred for
transplant from all over the country. All patients are initially
assessed at outpatient clinics. The patients and their familymem-
bers are counseled about the procedure and the potential risks
and benefits. Post-transplant patients are followed up initially
monthly for 3 months, every 3 months for 1 year, and every
6 months thereafter. Some of our patients come from outside
the city or country. These patients are followed up locally by
the referring oncologist or hematologist. If required, communica-
tion was maintained through electronic mail and telephone.
The pretransplant evaluation included the complete blood
count, liver and kidney function tests, infectious disease profile
(i.e., hepatitis B surfaceantigen, hepatitis Cantibody,HIVantibody,
cytomegalovirus, Mantoux test, and chest radiography), blood
group determination and coagulation testing, pulmonary function
tests, echocardiography, and a dental evaluation. A central line
(Hickman’s catheter) was inserted in all patients. All the patients
were admitted to a single room, and reverse barrier nursing was
practiced. Thepatientsprovidedwritten informedconsent for che-
motherapy, blood product administration, and transplantation.
Mobilized peripheral blood stem cells (PBSCs) were harvested
from all the patients. For mobilization, the patients received cyclo-
phosphamide 1.5 g/m2 followed by granulocyte colony-stimulating
factor (G-CSF) 5 mg/kg twice daily subcutaneously for 6 days. The
stemcellswereharvestedondays 5 to7usingeither theCobeSpec-
tra AutoPBSC or COMTEC (Fresenius Kabi, Bad Homberg, Germany,
https://www.terumobct.com) system and the default software
configuration recommended by the manufacturer. The mononu-
clear cells were counted manually.
For multiple myeloma, the patients received high-dose mel-
phalan (200 mg/m2). For patients with HL and NHL, carmustine
(BCNU; 300 mg/m2), etoposide (200 mg/m2), cytarabine (ara-C;
200 mg/m2), and melphalan (140 mg/m2) were used.
Patientswere admitted to a single roomwith ahigh-efficiency
particulate air (HEPA) filter. Standard prophylaxis with ciproflox-
acin (500 mg twice daily or 20–30 mg/kg in 2 divided doses),
fluconazole (200mg once daily or 6mg/kg per day), and valaciclo-
vir (500 mg twice daily or 10 mg/kg twice daily) was started in all
patientsonday25.All patientswereprovidedaneutropenicdiet.
The autologous stem cells were reinfused on day 0 through the
central venous catheter and preceded by i.v. pheniramine mal-
eate (50 mg). G-CSF, 5 mg/kg, was started on day +1. All patients
received irradiated blood products. All packed red blood cell
transfusions were performed with a leukocyte filter, and febrile
neutropenia evaluations and treatmentwere performed in accor-
dance with the standard guidelines.
Engraftment was defined as achievement of an absolute neu-
trophil count of$0.53 109 per liter for 3 consecutive days. Plate-
let engraftmentwasdefinedasa countof$203109per literwith
transfusion independence. Patients were evaluated for response
using the World Health Organization criteria at 4 weeks after
transplant at the outpatient clinic with subsequent follow-up
examinations. In patients with multiple myeloma, the response
was assessed and monitored using serial immunoglobulin levels.
Patients with Ewing’s sarcoma or neuroblastoma were ex-
cluded from the analysis because of insufficient patient numbers.
The remaining patients were evaluable for the response and sur-
vival analyses. Overall survival was defined as that from the date
of transplant until death or the date of the last follow-up visit. The
curve for overall survival was plotted according to Kaplan and
Meier. Statistical analysis was performed using SPSS software,
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version 19.0 (IBM Corp., Armonk, NY, http://www-01.ibm.com/
software/analytics/spss/).
RESULTS
In thestudyperiod,a totalof206hematopoietic stemcell transplants
were performed at our center. Of these, 69 were autologous trans-
plants. Of the patients with lymphoma, 2 underwent the procedure
in the first CR. All others achievedmore than a 50% response to sal-
vage chemotherapy andunderwent theprocedure in the secondCR.
Hodgkin’sdiseasewas themost common indication (n=26, 38%) fol-
lowedbynon-Hodgkin’s lymphoma (n = 23, 33%),multiplemyeloma
(n=15,22%),Ewing’s sarcoma(n=4,6%), andneuroblastoma(n=1).
Owing to the small numbers, the patients with Ewing’s sarcoma and
neuroblastoma were excluded from the analysis. Before transplan-
tation,allpatientshadchemosensitivedisease.Thesalvageregimens
for thepatientswith lymphomaincludeddexamethasone,Ara-C,and
cisplatin in 29 patients, ifosfamide, carboplatin, and etoposide in 16
patients, and etoposide, methylprednisolone, cytarabine, and cis-
platin in 4 patients. All 15 patients with multiple myeloma under-
went the procedure in the plateau phase. The median age 6 SD
was 346 13.1 years (range, 4–64). Of the 69 patients, 5 were in the
pediatric age group and the restwere adults (49men and20women).
The peripheral blood stemcellswere infused in 67 patients, and
2 patients received both peripheral and bone marrow progenitor
stem cells. A mean of 4.73 1086 1.7 mononuclear cells per kilo-
gram (range, 2.2–10) were infused. Of the 69 patients, 64 achieved
engraftment (93%), and 5 had primary graft failure, mainly because
of sepsis. The median time to white blood cell recovery was 18.26
5.34 days (range, 12.9–23.5). The median time to platelet transfu-
sion independencewas15days (range,12–40).Themedianduration
of antibiotic therapy secondary to febrile neutropenia was 13 days.
Thehospitalstaywasrangedfrom11to52days(median6SD,2868).
A total of 149 febrile episodes were documented in 41 patients.
Central line-associated bloodstream infections were present in
12 patients. The common organisms were Staphylococcus species
and Escherichia. coli. Ten patients developed bloodstream infec-
tions (BSIs). Themost commonorganismwas E. coli (Fig. 1). During
the hospital stay, 13 patients (19%) required intensive care unit ad-
mission. In1patient, the sputumcultureand sensitivity testingwas
positive for Aspergillus flavus. The computed tomography scan of
the chest showeda fungal ball thatwas subsequently removed sur-
gically. Transplant-related mortality for all evaluable patients was
15%. The cause of death for transplant-related mortality was
mainly sepsis (Table 1). After a median follow-up of 104 months,
the overall survival rate was 86% (Fig. 2). One transplant-related
mortality (TRM) occurred in a patient with multiple myeloma,
and the overall survival was 93%. For patients with non-Hodgkin’s
lymphoma, the TRMratewas 25%and the overall survival ratewas
approximately 70%. The TRM for patients with Hodgkin’s disease
was12%. Theoverall survival for these patientswas71%. Theover-
all survival according to the diagnosis is shown in Figure 3.
DISCUSSION
The rationale of the present studywas to compile data on the fre-
quency, complications, and overall survival after autologous
transplant performed in the past decade at our center. The two
main indicationswere lymphomaandmultiplemyeloma, in accor-
dance with the frequency reported from the CIBMTR, EBMT, and
India [10]. TheuseofPBSCs forautologousandallogeneic transplan-
tation has increased significantly in recent years. According to the
CIBMTR, inmore than 95%of autologous stemcell transplants,mo-
bilizedPBSCareused.TheadvantagesofusingPBSCs includeashorter
engraftment time, fewer transfusions, a shorter hospital stay, the
convenience of stem cell collection, and rapid restoration of the
immune system [11]. In 97% of our patients, PBSCs were used. In
the 2 patients who had received bone marrow stem cells, no dif-
ference was found in the engraftment time or hospital stay. The
relatively late engraftment resulted from the late presentation
andpretreatmentwithhighdosesofcytotoxicchemotherapy in these
patients. Five patients experienced primary graft failure and multi-
ple organ failure, which contributed to the overall mortality. Most
of these deaths were in the initial years of the transplant program.
Figure 1. Frequency of CLABSI and BSI organisms. Abbreviations:
BSI, bloodstream infection; CLABSI, central line-associated blood-
stream infection.
Table 1. Causes of transplantation-related mortality
Pt. No. Age (yr) Diagnosis Toxicity
1 62 NHL Sepsis, NSTEMI, cardiogenic
shock, graft failure
2 35 HL Sepsis
3 49 HL Sepsis, ARDS, cardiomyopathy
4 52 NHL Acute renal and liver failure,
graft failure
5 59 HL Sepsis
6 42 NHL Sepsis, MOF
7 45 NHL Sepsis, ARF
8 20 NHL Pneumonia, respiratory
failure, graft failure
9 39 MM Sepsis, graft failure
10 24 HL Sepsis, graft failure
Abbreviations: ARDS, acute respiratory distress syndrome; ARF, acute
renal failure; HD, Hodgkin’s lymphoma; MM, multiple myeloma; MOF,
multiorgan failure; NHL, non-Hodgkin’s lymphoma; NSTEMI,
non-ST-segment elevationmyocardial infarction; Pt. No., patient number.
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Once the learning curve had been completed, the mortality rate
decreased from 21% in 2004–2009 to 8% in 2010–2014. The
median 6 SD age was 34 6 13.1 years. Studies reported from
the region have shown themedian age tobe45 years, in particular,
for NHL [12]. Our study reported a much younger age of presen-
tation. This younger age group preponderance has been reported
previously in other hematological and nonhematological malig-
nancies [13–15] from our region, consolidating that cancer, in
our population, has a predilection for a younger population.
The major gastrointestinal toxicities observed were grade III
to IV nausea/vomiting, diarrhea, and mucositis. These toxicities
were higher in patients with multiple myeloma owing to the
high-dose melphalan conditioning therapy. The incidence of or-
gan toxicities (e.g., real dysfunction [16], veno-occlusive disease
[17], and pulmonary [18], cardiac [19], and central nervous system
toxicity [20]) was similar to that reported in published studies and
did not differ according to the type of conditioning therapy used.
In the present study, 7% of patients died of regimen-related
toxicity. The CIBMTR data reported 12%mortality from regimen-
related toxicity in their series [21]. Infections due to myelosup-
pression remain the major cause of morbidity andmortality until
day 100. Management of febrile neutropenia was in accordance
with institutional guidelines. First-line i.v. antibiotic therapy con-
sisted of piperacillin/tazobactam and amikacin. If a patient re-
mained febrile after 48–72 hours, the regimen was changed to
imipenem/cilastatin, vancomycin, and amphotericin B (conven-
tional). For afebrile patients, the initial antibiotic regimen was con-
tinued until the resolution of neutropenia. Our patients mainly
developed E. coli bloodstream infections (isolated from blood cul-
ture). Similar results were reported previously in HSCT recipients
in a retrospective study that investigated the effect of BSI on the
outcome of 246 allogeneic transplant recipients [22]. Gram-
negative rods constituted 54% of the bacterial isolates. Hospital-
acquired infections mainly due to Acinetobacter baumannii [23]
and carbapenem-resistant E. coli are an issue at our center. All
our transplants are performed in single rooms with HEPA filters.
Because of the increased frequency of possible fungal infections,
the hospital policy is to start amphotericin B early if the fever does
not resolve or if radiological signs suggestive of fungal infection are
present. Debilitating fungal infection was observed in 1 patient
only at our center and required surgical removal. Mycobacterium
tuberculosis infectionhasbeen reportedoccasionally inbothautol-
ogous and allogeneic transplant recipients, possibly due to reacti-
vation after themyelosuppression caused by conditioning therapy
[24]. Only 1 patient developed M. tuberculosis in our series.
Several observational and clinical trials havebeen conductedof
patients with NHL and HL. The 5-year survival after transplant in
these patients is approximately 50%–60% [25, 26]. The most com-
mon cause of treatment failure is relapse or disease progression.
This predominantly occurs in the first 2 years after the procedure.
Our cohort of patients with NHL and HL showed that after
a median 6 SE follow-up of 23.4 6 4.3 months (range, 14.8–32),
the overall survival was 70% and 71.4%, respectively. Most of our
patients with NHL had diffuse large B-cell lymphoma (DLBCL) in sec-
ond remission. The role of ASCT during first remission as consolida-
tivetherapy inpatientswithDLBCLremainscontroversialandshould
not be performed outside the clinical trial setting [27]. Bolwell et al.
[28] in 2002 reporteda5-year overall survival rateof 43% inpatients
with NHL and high-grade histologic findings. Our results are compa-
rabletotheirdata.Philipetal., inamulticenter,prospective random-
ized trial, also compared autologous HSCT and nontransplant
salvage therapy and showed that autologous HSCT is the standard
of care for patients younger than 60 years old with chemotherapy-
sensitive relapsed or primary refractory aggressive NHL [29].
High-dose therapy with melphalan (200 mg/m2), followed by
ASCT in combinationwithnovel agents is considered the standard
of care for patients with newly diagnosed multiple myeloma. In
our cohort of patients with MM, all were younger than 65 years
old. The median age6 SD was 486 7.5 years (range, 32–55). A
recent, open-label, randomized phase 3 trial comparing high-
dose melphalan followed by ASCT and melphalan, prednisolone,
and lenalidomide showed significantly longer progression-free
and overall survival [30]. Other studies of younger patients have
shown overall survival rates ranging from 48.3% to 66% [31, 32].
Compared with this, our patients did relatively better, with an
overall survival of approximately 93%. All these patients were re-
ceivingmaintenance therapywith either thalidomide or lenalido-
mide at the last follow-up visit.
Figure 2. Overall survival.
Figure 3. Overall survival according to diagnosis.
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In a retrospective analysis, the median cost of autologous
transplant at our institution was approximately $20,000 (range,
$10,000–$35,000). This cost includes the cost of chemotherapy,
stemcell/bonemarrowharvest,antibioticusage,bloodand/orblood
product transfusion and growth factor support, the daily bed and in-
vestigation charges, and theconsultation fees. The costof clinic visits
and subsequent admissionswas omitted. Our data clearly show that
the cost of stem cell transplant is less expensive in Pakistan than in
developed countrieswith similar success rates. Themajor contribut-
ing factors to thecost andoverallmortality includedebilitating infec-
tionsand regimen-related toxicities thatprolonged thehospital stay.
CONCLUSION
Weobserved survival rates similar to those in the international data
for non-Hodgkin’s andHodgkin’s lymphoma. Higher response rates
and reduced morbidity and mortality in patients with multiple my-
eloma resulted from their younger age and proper case selection.
Overall, the results suggest that with improved management of
infections and conditioning-related toxicities, it is possible to de-
velop hematopoietic stem cell transplant programs in third-world
countries and achieve outcomes comparable to those in the inter-
national data.
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